vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $12.5M, roughly 1.1× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -34.7%, a 36.0% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -0.7%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
FENC vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $12.5M |
| Net Profit | $-4.8M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -18.5% | 1.5% |
| Net Margin | -34.7% | 1.3% |
| Revenue YoY | 73.8% | -0.7% |
| Net Profit YoY | -141.1% | 129.2% |
| EPS (diluted) | $-0.17 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $12.5M | ||
| Q3 25 | $12.5M | $14.6M | ||
| Q2 25 | $9.7M | $20.4M | ||
| Q1 25 | $8.8M | $14.6M | ||
| Q4 24 | $7.9M | $12.6M | ||
| Q3 24 | $7.0M | $16.9M | ||
| Q2 24 | $7.3M | $13.0M | ||
| Q1 24 | $25.4M | $9.9M |
| Q4 25 | $-4.8M | $163.0K | ||
| Q3 25 | $-638.0K | $-1.1M | ||
| Q2 25 | $-3.2M | $2.7M | ||
| Q1 25 | $-1.2M | $80.0K | ||
| Q4 24 | $-2.0M | $-559.0K | ||
| Q3 24 | $-5.7M | $3.0M | ||
| Q2 24 | $-5.6M | $856.0K | ||
| Q1 24 | $12.8M | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | -18.5% | 1.5% | ||
| Q3 25 | -1.5% | -5.4% | ||
| Q2 25 | -28.3% | 9.4% | ||
| Q1 25 | -9.2% | 1.8% | ||
| Q4 24 | -11.8% | -1.8% | ||
| Q3 24 | -74.6% | 19.0% | ||
| Q2 24 | -69.4% | 8.0% | ||
| Q1 24 | 54.2% | 11.3% |
| Q4 25 | -34.7% | 1.3% | ||
| Q3 25 | -5.1% | -7.7% | ||
| Q2 25 | -32.7% | 13.1% | ||
| Q1 25 | -13.3% | 0.5% | ||
| Q4 24 | -25.0% | -4.4% | ||
| Q3 24 | -82.2% | 18.1% | ||
| Q2 24 | -76.5% | 6.6% | ||
| Q1 24 | 50.6% | 9.0% |
| Q4 25 | $-0.17 | $0.00 | ||
| Q3 25 | $-0.02 | $-0.02 | ||
| Q2 25 | $-0.11 | $0.04 | ||
| Q1 25 | $-0.04 | $0.00 | ||
| Q4 24 | $-0.02 | $0.00 | ||
| Q3 24 | $-0.21 | $0.04 | ||
| Q2 24 | $-0.20 | $0.01 | ||
| Q1 24 | $0.41 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.5M | $17.6M |
| Total Assets | $70.6M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | $1.3M | ||
| Q3 25 | $21.9M | $429.0K | ||
| Q2 25 | $18.7M | $4.1M | ||
| Q1 25 | $22.7M | $1.8M | ||
| Q4 24 | $26.6M | $1.4M | ||
| Q3 24 | $40.3M | $2.9M | ||
| Q2 24 | $43.1M | $2.4M | ||
| Q1 24 | $51.2M | $2.0M |
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
| Q4 25 | $35.5M | $17.6M | ||
| Q3 25 | $-4.5M | $17.2M | ||
| Q2 25 | $-7.5M | $18.2M | ||
| Q1 25 | $-5.9M | $15.2M | ||
| Q4 24 | $-5.9M | $14.9M | ||
| Q3 24 | $-5.2M | $15.2M | ||
| Q2 24 | $-1.4M | $11.9M | ||
| Q1 24 | $3.0M | $5.0M |
| Q4 25 | $70.6M | $50.1M | ||
| Q3 25 | $49.3M | $54.0M | ||
| Q2 25 | $44.9M | $60.0M | ||
| Q1 25 | $46.4M | $57.0M | ||
| Q4 24 | $44.9M | $50.0M | ||
| Q3 24 | $58.9M | $48.0M | ||
| Q2 24 | $63.2M | $40.8M | ||
| Q1 24 | $69.2M | $38.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $1.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $1.8M | ||
| Q3 25 | $1.5M | $-2.5M | ||
| Q2 25 | $-3.7M | $-654.0K | ||
| Q1 25 | $-4.3M | $-7.2M | ||
| Q4 24 | $-1.5M | $2.2M | ||
| Q3 24 | $-2.2M | $4.2M | ||
| Q2 24 | $-8.4M | $-565.0K | ||
| Q1 24 | $39.0M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-404.0K | ||
| Q3 24 | — | $2.8M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.2% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | — | -8.0% | ||
| Q1 24 | — | -39.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 20.6% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | 3.04× | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
